[Combination therapy of insulin sensitizer and sulfonylurea].
Hari
J
J
Department of Internal Medicine, Hyogo Prefectural Kakogawa Hospital.
D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000008:administration & dosage* / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077205:Pioglitazone; D011498:Protein Precursors / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013844:Thiazoles / Q000008:administration & dosage* / Q000494:pharmacology; D045162:Thiazolidinediones; D000077288:Troglitazone
D001786:Blood Glucose; D002839:Chromans; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D011498:Protein Precursors; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; C040839:pre-hemoglobin A, glycosylated